Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Omeros Corporation
Private Company Edition: Publicly held Ascendis outsourced its preclinical AMD program to private Eyconis. Also, Innovation Endeavors revealed a new $630m VC fund and Mirae raised $50m for its first life science fund, while Accent, Comanche and Tr1X each brought in $75m rounds.
Deal Snapshot: The Roche subsidiary will use GenEdit’s hydrophilic nanoparticles to develop genetic medicines for autoimmune diseases meant to overcome the limitations of existing delivery methods.
Development of narsoplimab in the kidney disease has been called off, making a forthcoming regulatory decision in a different use all the more important.
A Phase III hit is always nice but a lot more information will be required to judge iptacopan’s market potential.
- Site Specific
- Drug Delivery
- Large Molecule
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.